Wird geladen...

Trial Watch: Toll-like receptor agonists in cancer immunotherapy

Toll-like receptor (TLR) agonists demonstrate therapeutic promise as immunological adjuvants for anticancer immunotherapy. To date, three TLR agonists have been approved by US regulatory agencies for use in cancer patients. Additionally, the potential of hitherto experimental TLR ligands to mediate...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncoimmunology
Hauptverfasser: Smith, Melody, García-Martínez, Elena, Pitter, Michael R., Fucikova, Jitka, Spisek, Radek, Zitvogel, Laurence, Kroemer, Guido, Galluzzi, Lorenzo
Format: Artigo
Sprache:Inglês
Veröffentlicht: Taylor & Francis 2018
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6279325/
https://ncbi.nlm.nih.gov/pubmed/30524908
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1526250
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!